PharmAust SWOTAnalysis
It is a worthwhile exercise to review ones investments from time to time. I thought I would do a basic SWOT analysis to reassure myself that I am invested for the right reasons.
The following is merely my own non-scientific observations of how PAA is generally situated at the moment.
Strengths
· Monepantel has demonstrated meaningful results in all testing to date and has a strong safety profile
· There are multiple shots at goal – Covid, K9 Lymphoma, Human Cancers, MND
· Profitable In-house laboratory – Epichem
· Knowledgeable and experienced scientific leadership
· Financial prudence
· IP protections
· Tightly held Share Register
Weaknesses
· Small team
· Marketing and promotion under par
· Failure to cement Elanco option
Opportunities
· Huge addressable markets
· Breakthrough therapeutics – potential Government funding
· Potential collaborators and/or partnerships
· Potential takeover target
Threats
· Failure to achieve required results in Covid testing would erode share price and confidence
· $$$ Big pharma may not like their lucrative vaccine revenue streams disrupted
· Emerging competitors may grab limelight
My estimation is that the strengths and opportunities outweigh the weaknesses and threats.
This is a general overview from my perspective only. I’m renowned for sometimes missing the obvious so if I’ve overlooked anything, as always - do your own research…
GLTAH, Thrifty
- Forums
- ASX - By Stock
- PAA
- Ann: Appendix 4C and Quarterly Update
Ann: Appendix 4C and Quarterly Update, page-57
-
-
- There are more pages in this discussion • 50 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAA (ASX) to my watchlist
|
|||||
Last
20.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $97.24M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 16250 | 20.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
20.0¢ | 356146 | 8 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 16250 | 0.200 |
6 | 318669 | 0.195 |
14 | 909709 | 0.190 |
13 | 272647 | 0.185 |
20 | 440687 | 0.180 |
Price($) | Vol. | No. |
---|---|---|
0.200 | 356146 | 8 |
0.205 | 272264 | 4 |
0.210 | 382862 | 6 |
0.215 | 328018 | 3 |
0.220 | 479713 | 7 |
Last trade - 07.33am 01/08/2024 (20 minute delay) ? |
Featured News
PAA (ASX) Chart |
Day chart unavailable
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO
Anthony Noble
CEO
SPONSORED BY The Market Online